4-甲氧基-3-(三氟甲基)苯甲醛 | 50823-87-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲氧基-3-(三氟甲基)苯甲醛
• 中文别名: 3-三氟甲基-4-甲氧基苯甲醛；4-甲氧基-3-三氟甲基苯甲醛
• 英文名称: 4-methoxy-3-(trifluoromethyl)benzaldehyde
• 英文别名: 3-(trifluoromethyl)-4-methoxybenzaldehyde
• CAS: 50823-87-5
• 化学式: C₉H₇F₃O₂
• 分子量: 204.149
• InChiKey: UMZQFCFPWAFMRL-UHFFFAOYSA-N

物化性质

• 熔点：
  38-40°C
• 沸点：
  251.1±40.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-甲氧基-3-(三氟甲基)苯甲醛 在 盐酸 、 sodium tetrahydroborate 、 吡啶盐酸盐 作用下， 以 乙醇 、 水 为溶剂， 反应 26.83h， 生成 1-[4-hydroxy-3-(trifluoromethyl)benzyl]imidazole-2-thione
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008
• 作为产物：
  描述：

  4-甲氧基-3-三氟甲基苯甲酸 在 N-甲基吗啉 、 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 4-甲氧基-3-(三氟甲基)苯甲醛
  参考文献：
  名称：

  伊马替尼的1,2,3-三唑和1,3,4-恶二唑衍生物的合成及生物学评价

  摘要：

  制备了伊马替尼的三个新系列的1,2,3-三唑和1,3,4-恶二唑衍生物，并在体外评估了它们对人慢性髓性白血病（K562），急性髓性白血病（HL60）和人白血病干样细胞系（KG1a）。通过确定每种伊马替尼类似物的抑制率来分析结构与活性之间的关系。苯和哌嗪环是这些化合物中维持对K562和HL60细胞系抑制活性所必需的基团。引入三氟甲基基团显着增强了化合物对这两种细胞系的效力。出人意料的是，某些化合物对KG1a细胞显示出显着的抑制活性，而没有抑制常见的白血病细胞系（K562和HL60）。

  DOI：

  10.1016/j.bmcl.2016.01.068

文献信息

• [EN] 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS<br/>[FR] DERIVES DE PIPERIDINE 1,4 DISUBSTITUEE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BETAHSD1
  申请人：ASTRAZENECA AB

  公开号：WO2004033427A1

  公开（公告）日：2004-04-22

  The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11βHSD1 is described.

  使用式(I)的化合物制造用于抑制11βHSD1的药物。
• Ir(<scp>iii</scp>)-catalyzed<i>ortho</i>C–H alkylations of (hetero)aromatic aldehydes using alkyl boron reagents
  作者：Xiao-Yang Chen、Erik J. Sorensen

  DOI：10.1039/c8sc03606c

  日期：——

  Transition-metal-catalyzed C–H alkylation reactions directed by aldehydes or ketones have been largely restricted to electronically activated alkenes. Herein, we report a general protocol for the Ir(III)-catalyzed ortho C–H alkylations of (hetero)aromatic aldehydes using alkyl boron reagents as the coupling partner. Featuring aniline as an inexpensive catalytic ligand, the method was compatible with

  由醛或酮引导的过渡金属催化的 C-H 烷基化反应在很大程度上仅限于电子活化的烯烃。在此，我们报告了使用烷基硼试剂作为偶联伙伴的 Ir(III) 催化的（杂）芳香醛的邻位 C–H 烷基化的通用方案。该方法以苯胺作为廉价的催化配体为特色，与多种苯甲醛、杂环醛、烷基三氟硼酸钾以及一些 α,β-不饱和醛相容。还成功获得了苯甲醛邻位C-H铱中间体的X射线晶体结构。
• Di-heterocyclic compounds and their use as antiviral agents
  申请人：Sterling Drug Inc.

  公开号：US04843087A1

  公开（公告）日：1989-06-27

  Compounds of the formulas: ##STR1## wherein Het is an oxazole or oxazine moiety; X is O, S or SO, n is an integer from 3 to 9, Y is an aliphatic bridge; and the various R groups represent hydrogen or various substituents as described herein, are useful as antiviral agents, especially against picornaviruses. N-(Chloroalkyl)amide intermediates for the compounds of Formula I are also active as antiviral agents. Related compounds outside the scope of the above formulas are also disclosed.

  公式化合物：##STR1## 其中Het是噁唑或噁唑啉基团；X是O、S或SO，n是从3到9的整数，Y是脂肪桥；各种R基团代表氢或如本文所述的各种取代基，可用作抗病毒剂，特别是对抗小RNA病毒。用于公式I化合物的N-(氯烷基)酰胺中间体也作为抗病毒剂活性。还披露了超出上述公式范围的相关化合物。
• ANTI-HIV COMPOUNDS
  申请人：Prosetta Antiviral, Inc.

  公开号：US20160168100A1

  公开（公告）日：2016-06-16

  This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.

  这项发明提供了用于治疗病毒感染的四氢异喹啉等化合物，含有这类化合物的药物配方，以及抑制病毒（如HIV）复制或治疗疾病（如艾滋病）的方法。
• NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Lee Sung Sook

  公开号：US20120028963A1

  公开（公告）日：2012-02-02

  The present invention relates to hydroxamate derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the compositions, and a method for preparing the hydroxamate derivatives.

  本发明涉及羟肟酸衍生物、其同分异构体、药用可接受的盐、水合物或溶剂化物，以及它们用于制备药物组合物的用途，包含它们的药物组合物，使用该组合物治疗疾病的方法，以及制备羟肟酸衍生物的方法。